Phaseline

Targets › CHRM4

CHRM4 (Muscarinic acetylcholine receptor M4): drug programs, companies and trials

4 programs from 2 companies in 13 trials: 7 Phase 3, 5 Phase 1, 1 Phase 2; Other, Psychiatry, Neurology; next expected readout Nov 2026.

The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase. (UniProt, P08173)

Open in Phaseline: the race on CHRM4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Bristol-Myers SquibbXanomeline
Muscarinic acetylcholine receptor M4 agonist; Muscarinic acetylcholine receptor M1 agonist
CHRM4, CHRM1Phase 3Alzheimer Disease; Alzheimer's Disease; Healthy Volunteers; SCHIZOPHRENIA 1 (Disorder)Mar 2027
Bristol-Myers SquibbXanomeline (BMS-986519)
Muscarinic acetylcholine receptor M4 agonist; Muscarinic acetylcholine receptor M1 agonist
CHRM4, CHRM1Phase 3SchizophreniaMar 2030
AstraZenecaGlycopyrronium
Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M1 antagonist; Muscarinic acetylcholine receptor inhibitor
CHRM3, CHRM1, CHRM4, CHRM2, CHRM5Phase 2AsthmaMay 2029
Bristol-Myers SquibbBMS-986521
M4 muscarinic acetylcholine receptor antagonist
CHRM4Phase 1Healthy VolunteersNov 2026

Conditions

Healthy Volunteers (4) Alzheimer Disease (3) Alzheimer's Disease (3) SCHIZOPHRENIA 1 (Disorder) (1) Schizophrenia (1) Asthma (1)

Modalities

small molecule (3)

Companies

Bristol-Myers Squibb (3) AstraZeneca (1)

Related targets

CHRM1 (3) CHRM3 (1) CHRM2 (1) CHRM5 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.